Brokers Issue Forecasts for Sanara MedTech FY2026 Earnings

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Sanara MedTech in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will earn ($1.65) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $46.00 price target on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. The business had revenue of $23.43 million during the quarter, compared to analyst estimates of $23.48 million.

Separately, HC Wainwright increased their price target on shares of Sanara MedTech from $51.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, May 15th.

Sanara MedTech Stock Performance

NASDAQ:SMTI traded up $0.12 during midday trading on Wednesday, hitting $28.81. The company's stock had a trading volume of 55,067 shares, compared to its average volume of 27,075. Sanara MedTech has a fifty-two week low of $25.86 and a fifty-two week high of $39.08. The firm's 50 day moving average is $30.43 and its 200-day moving average is $32.63. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.23 and a quick ratio of 2.02. The firm has a market cap of $256.06 million, a P/E ratio of -29.10 and a beta of 1.35.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP grew its position in shares of Sanara MedTech by 116.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 15,925 shares of the company's stock valued at $529,000 after acquiring an additional 8,567 shares during the period. Citadel Advisors LLC grew its holdings in Sanara MedTech by 7.3% in the fourth quarter. Citadel Advisors LLC now owns 21,984 shares of the company's stock valued at $730,000 after purchasing an additional 1,491 shares during the period. BNP Paribas Financial Markets purchased a new stake in shares of Sanara MedTech in the fourth quarter valued at approximately $106,000. Renaissance Technologies LLC raised its stake in shares of Sanara MedTech by 152.9% during the 4th quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock worth $1,175,000 after buying an additional 21,400 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Sanara MedTech by 0.9% during the 4th quarter. Northern Trust Corp now owns 40,816 shares of the company's stock worth $1,355,000 after buying an additional 358 shares during the period. Hedge funds and other institutional investors own 8.10% of the company's stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.